Table 2—

Effects of therapeutic regimes

PlaceboNateglinide 120 mgTroglitazone 600 mgNateglinide 120 mg and Troglitazone 600 mg
Lipid parameters*
 Total cholesterol+ 0.05− 0.03+ 0.35+ 0.30
 LDL cholesterol− 0.05− 0.01+ 0.19+ 0.17
 HDL cholesterol+ 0.02+ 0.02+ 0.12+ 0.11
 Triglycerides+ 0.12− 0.2− 0.37− 0.29
Weight*− 0.23+ 0.53+ 0.50+ 2.31
 Number discontinued0010
Suggestive hypoglycemia7241849
 Percent of total4.71611.932.7
Confirmed hypoglycemia31210
 Percent of total2.00.71.36.7
Changes in liver enzymes2187
 Number discontinued2074
Hematocrit >20% decrease01.32.00
  • *

    * Adjusted mean changes from baseline.